Product List
IFI44L Antibody
CUSABIO produces the IFI44L antibody by immunizing rabbits with recombinant human IFI44L protein (amino acids 206-307) and subsequently purifying the antibody using protein G from rabbit antiserum. The antibody is available as an unconjugated IgG with a purity exceeding 95%. It demonstrates reactivity with both human and mouse IFI44L protein. IFI44L has been identified as a novel tumor suppressor that influences cancer stemness, metastasis, and drug resistance by regulating the Met/Src signaling pathway in hepatocellular carcinoma (HCC). This antibody can serve as a valuable prognostic marker. This anti-IFI44L antibody has been validated for use in ELISA, immunofluorescence (IF), and Western blot (WB) applications.
ZBTB46 Antibody
The ZBTB46 antibody is generated in rabbits against a partial protein sequence corresponding to amino acids 174-362 of the human ZBTB46 protein. It is supplied as the unconjugated IgG isoform and exhibits a purity exceeding 95% using protein G purification. This antibody demonstrates reactivity towards both human and mouse ZBTB46 protein. It has undergone rigorous quality control testing for its suitability in ELISA, Western blotting, and Immunohistochemistry applications. Its target protein, ZBTB46, is prominently expressed in quiescent endothelial cells and functions as a shear-sensitive transcription factor. It exerts its regulatory influence by suppressing endothelial cell proliferation through the modulation of cell cycle protein expression.
Introduction
Polyclonal antibodies are a diverse group of antibodies produced by different B cell clones in the body. They recognize and bind to multiple epitopes on a single antigen. Unlike monoclonal antibodies, which are derived from a single B cell clone and recognize a single epitope, polyclonal antibodies are heterogeneous and can target various sites on an antigen. They are classified based on their source (e.g., rabbit, goat, mouse) and the type of antigen they target (e.g., proteins, peptides, small molecules).
Key Biological Properties: Polyclonal antibodies are characterized by their ability to recognize multiple epitopes, which enhances their binding strength and specificity. They are typically produced in response to an antigenic stimulus and can be found in the serum of immunized animals.
Expression Patterns: Polyclonal antibodies are produced by B cells in response to antigen exposure. The expression patterns depend on the immunization protocol and the animal species used.
Tissue Distribution: These antibodies are primarily found in the blood serum but can also be present in other body fluids and tissues, depending on the immune response and the distribution of the antigen.
Primary Biological Functions: Polyclonal antibodies play a crucial role in the immune system by recognizing and neutralizing pathogens, such as bacteria and viruses. They facilitate the clearance of antigens through various immune mechanisms, including opsonization, complement activation, and antibody-dependent cellular cytotoxicity (ADCC).
Role in Immune Responses: Polyclonal antibodies are essential for the adaptive immune response. They provide a broad and robust defense against pathogens by targeting multiple epitopes, which reduces the likelihood of immune evasion by the pathogen.
Pathogen Recognition: These antibodies recognize and bind to specific antigens on the surface of pathogens, marking them for destruction by other immune cells.
Mechanisms with Other Molecules and Cells: Polyclonal antibodies interact with various immune cells, such as macrophages, neutrophils, and natural killer (NK) cells, to mediate immune responses. They can also bind to Fc receptors on immune cells, enhancing phagocytosis and cytotoxicity.
Binding Partners: The primary binding partners of polyclonal antibodies are antigens, which can be proteins, peptides, or other molecules. They can also interact with complement proteins and Fc receptors.
Downstream Signaling Cascades: Upon binding to their target antigens, polyclonal antibodies can trigger downstream signaling cascades that lead to the activation of immune responses. This includes the activation of the complement system, which enhances opsonization and lysis of pathogens.
Expression and Activity Control: The production and activity of polyclonal antibodies are regulated by various factors, including the nature of the antigen, the immunization protocol, and the host’s immune system.
Transcriptional Regulation: The expression of polyclonal antibodies is controlled at the transcriptional level by cytokines and other signaling molecules that influence B cell activation and differentiation.
Post-Translational Modifications: Polyclonal antibodies can undergo post-translational modifications, such as glycosylation, which can affect their stability, binding affinity, and effector functions.
Biomedical Research: Polyclonal antibodies are widely used in research for detecting and quantifying proteins, studying protein-protein interactions, and investigating cellular pathways.
Diagnostic Tools: They are used in various diagnostic assays, such as ELISA, Western blotting, and immunohistochemistry, to detect the presence of specific antigens in samples.
Therapeutic Strategies: Polyclonal antibodies are used in therapeutic applications, such as antivenoms, immunoglobulin replacement therapy, and passive immunization against infectious diseases.
Development: Polyclonal antibodies are produced throughout an individual’s life in response to antigen exposure. They play a critical role in the development of the immune system by providing protection against pathogens.
Aging: As individuals age, the production and diversity of polyclonal antibodies may decline, leading to a reduced ability to respond to new antigens and an increased susceptibility to infections.
Disease: Polyclonal antibodies are involved in various diseases, including autoimmune disorders, where they may target self-antigens, and infectious diseases, where they provide protection against pathogens.
